Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06412952
EARLY_PHASE1

68Ga-NOTA-RM26 PET/CT in Glioma Patients

Sponsor: Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2022-10-01

Completion Date

2024-05-31

Last Updated

2024-05-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

68Ga-RM26

Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.

Locations (1)

Chinese Academy of Medical Science & Peking Union Medical College Hospital

Beijing, Beijing Municipality, China